During Tuesday’s Morning trade, Shares of Pulte Group, Inc. (NYSE:PHM), gained 0.44% to $19.34.
Pulte Group, will present at the Citigroup’s 2015 Basic Materials Conference on Wednesday, December 2, 2015, at 1:15 pm (ET).
Pulte Group, Inc., through its auxiliaries, engages in the homebuilding business; mortgage banking operations; and title operations in the United States. The company is involved in the acquisition and development of land primarily for residential purposes; and the construction of housing on land.
Shares of Exelixis, Inc. (NASDAQ:EXEL), declined -1.08% to $5.49, during its current trading session.
Exelixis, declared the presentation of positive overall survival (OS) results from coBRIM, the phase 3 pivotal trial evaluating COTELLIC™ (cobimetinib) in patients with formerly untreated resectable, locally advanced or metastatic melanoma carrying a BRAF V600E or V600K mutation, in combination with vemurafenib. Dr. Victoria Atkinson, Medical Oncologist at Princess Alexandra Hospital, Queensland, Australia, presented the data during a late-breaking abstract oral presentation this afternoon at the Society for Melanoma Research (SMR) 2015 International Congress, which is being held November 18-21 in San Francisco. COTELLIC is a selective inhibitor of MEK that was discovered by Exelixis and is now the subject of a worldwide partnership agreement between Exelixis and Genentech, a member of the Roche Group.
In October 2015, Exelixis declared the coBRIM trial met its OS secondary endpoint, demonstrating a statistically noteworthyimprovement in OS for the combination of COTELLIC and vemurafenib contrast to vemurafenib monotherapy. Recently’s presentation was the first to comprise detailed data on the endpoint. The median OS was 22.3 months for the combination of COTELLIC and vemurafenib as compared to 17.4 months for vemurafenib alone, corresponding to a 30% reduction in the rate of death for the combination as contrast to vemurafenib alone (hazard ratio [HR]=0.70, 95% confidence interval [CI] 0.55-0.90, p= 0.005). Ongoing study monitoring did not identify any new safety signals.
“The overall survival benefit for COTELLIC and vemurafenib observed in the coBRIM trial further underscores the positive impact that the combination of these two therapies can have on the treatment of advanced BRAF V600 mutation-positive melanoma,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
Finally, Shares of Aetna Inc (NYSE:AET), lost -0.18%, and is now trading at $105.52.
Aetna and The Children’s Hospital of Philadelphia, declared a new accountable care organization (ACO) partnership designed to improve the quality of care and lower health care costs through more coordinated care. This is Aetna’s first pediatric ACO arrangement.
Under the contract, members of Aetna commercial plans (up to age 19) in the five-county Philadelphia area and Burlington County, N.J., and who receive care from CHOP physicians, became part of the program.
The agreement is part of Aetna’s strategy to transition from fee-for-service reimbursement to value-based payment. Value-based arrangements are emerging as a solution to address rising health care costs, reduce duplication of services, improve health outcomes, and make it easier for people to get the care they need. In value-based models, doctors and hospitals are paid for assisting keep people healthy and for improving the health of those who have chronic conditions in an evidence-based, cost-effective way.
Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit administration services, dental, behavioral health, and vision plans on an insured basis, and an employer-funded or administrative basis.